Sanofi agrees to license infectious disease assets to Evotec

02:23 EDT 19 Jun 2018 | Pharmaceutical Business Review

Evotec has signed an agreement to integrate Sanofi’s infectious disease unit into its fold as part of a move to create an infectious disease open innovation research and development (R&D) platform in France.

Original Article: Sanofi agrees to license infectious disease assets to Evotec


More From BioPortfolio on "Sanofi agrees to license infectious disease assets to Evotec"

Quick Search


Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...